Xingnaojing for Moderate-to-severe Acute ischemic Stroke (XMAS): study protocol for a randomized controlled trial
DiscussionThe results of this trial will provide critical evidence for XNJ in the treatment of AIS as a complementary approach that can be initiated after reperfusion therapy or when the AIS is not eligible for thrombolytic treatment.Trial registrationClinical Trials.gov, ID:NCT02728180. Registered on 28 March 2016.
Source: Trials - Category: Research Source Type: clinical trials
More News: Brain | Cardiology | Cardiovascular | China Health | Heart | Hemorrhagic Stroke | Ischemic Stroke | National Institutes of Health (NIH) | Neurology | Research | Stroke | Study | Thrombosis